160 related articles for article (PubMed ID: 15999028)
1. Rasmussen's syndrome: intractable epilepsy and progressive neurological deterioration from a unilateral central nervous system.
Carney PR
CNS Spectr; 2001 May; 6(5):398, 409-16. PubMed ID: 15999028
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis.
Rogers SW; Andrews PI; Gahring LC; Whisenand T; Cauley K; Crain B; Hughes TE; Heinemann SF; McNamara JO
Science; 1994 Jul; 265(5172):648-51. PubMed ID: 8036512
[TBL] [Abstract][Full Text] [Related]
3. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.
Varadkar S; Bien CG; Kruse CA; Jensen FE; Bauer J; Pardo CA; Vincent A; Mathern GW; Cross JH
Lancet Neurol; 2014 Feb; 13(2):195-205. PubMed ID: 24457189
[TBL] [Abstract][Full Text] [Related]
4. Unilateral holohemispheric central nervous system lesions associated with medically refractory epilepsy in the pediatric population: a retrospective series of hemimegalencephaly and Rasmussen's encephalitis.
Wang DD; Benkli B; Auguste KI; Garcia PA; Sullivan J; Barkovich AJ; Chang EF; Tihan T
J Neurosurg Pediatr; 2014 Dec; 14(6):573-84. PubMed ID: 25303156
[TBL] [Abstract][Full Text] [Related]
5. Physiological analysis of Rasmussen's encephalitis: patch clamp recordings of altered inhibitory neurotransmitter function in resected frontal cortical tissue.
Gibbs JW; Morton LD; Amaker B; Ward JD; Holloway KL; Coulter DA
Epilepsy Res; 1998 Jun; 31(1):13-27. PubMed ID: 9696297
[TBL] [Abstract][Full Text] [Related]
6. [Rasmussen's syndrome, an autoimmune disease].
Carrillo Herranz A; Sánchez Pérez I; Aparicio Meix JM; Lozano Giménez C; Roy Ariño G; Villar Gimerans LM; Sánchez Muñoz L
An Pediatr (Barc); 2003 Aug; 59(2):187-9. PubMed ID: 12882748
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures.
Mantegazza R; Bernasconi P; Baggi F; Spreafico R; Ragona F; Antozzi C; Bernardi G; Granata T
J Neuroimmunol; 2002 Oct; 131(1-2):179-85. PubMed ID: 12458050
[TBL] [Abstract][Full Text] [Related]
8. [A ten-year old boy with progressive neurologic outcome].
Sandvig I; Tennøe B; Eriksson AS
Tidsskr Nor Laegeforen; 2006 Mar; 126(6):779-81. PubMed ID: 16568569
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies and cell-mediated autoimmunity to NMDA-type GluRepsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua.
Takahashi Y; Mori H; Mishina M; Watanabe M; Kondo N; Shimomura J; Kubota Y; Matsuda K; Fukushima K; Shiroma N; Akasaka N; Nishida H; Imamura A; Watanabe H; Sugiyama N; Ikezawa M; Fujiwara T
Epilepsia; 2005; 46 Suppl 5():152-8. PubMed ID: 15987271
[TBL] [Abstract][Full Text] [Related]
10. Rasmussen's syndrome: progressive autoimmune multi-focal encephalopathy.
Freeman JM
Pediatr Neurol; 2005 May; 32(5):295-9. PubMed ID: 15866428
[TBL] [Abstract][Full Text] [Related]
11. Rasmussen's chronic encephalitis in adults.
McLachlan RS; Girvin JP; Blume WT; Reichman H
Arch Neurol; 1993 Mar; 50(3):269-74. PubMed ID: 8382920
[TBL] [Abstract][Full Text] [Related]
12. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis.
Wiendl H; Bien CG; Bernasconi P; Fleckenstein B; Elger CE; Dichgans J; Mantegazza R; Melms A
Neurology; 2001 Oct; 57(8):1511-4. PubMed ID: 11673604
[TBL] [Abstract][Full Text] [Related]
13. Globally altered microstructural properties and network topology in Rasmussen's encephalitis.
Held NR; Bauer T; Reiter JT; Hoppe C; Keil VCW; Radbruch A; Helmstaedter C; Surges R; Rüber T
Brain Commun; 2023; 5(6):fcad290. PubMed ID: 37953836
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to AMPA receptors in Rasmussen's encephalitis.
Nibber A; Clover L; Pettingill P; Waters P; Elger CE; Bien CG; Vincent A; Lang B
Eur J Paediatr Neurol; 2016 Mar; 20(2):222-227. PubMed ID: 26785913
[TBL] [Abstract][Full Text] [Related]
15. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins.
Whitney KD; McNamara JO
J Neurosci; 2000 Oct; 20(19):7307-16. PubMed ID: 11007888
[TBL] [Abstract][Full Text] [Related]
16. [Late onset Rasmussen's syndrome: clinical and therapeutic characteristics].
Jaillon-Riviere V; Dupont S; Bertran F; De La Sayette V; Beuvon F; Baulac M; Defer G
Rev Neurol (Paris); 2007 May; 163(5):573-80. PubMed ID: 17571025
[TBL] [Abstract][Full Text] [Related]
17. [Recent advances in pathogenic concepts and therapeutic strategies in Rasmussen's encephalitis].
Bahi-Buisson N; Nabbout R; Plouin P; Bulteau C; Delalande O; Hertz Pannier L; Dulac O; Chiron C
Rev Neurol (Paris); 2005 Apr; 161(4):395-405. PubMed ID: 15924075
[TBL] [Abstract][Full Text] [Related]
18. Rasmussen's syndrome.
Granata T
Neurol Sci; 2003 Oct; 24 Suppl 4():S239-43. PubMed ID: 14598051
[TBL] [Abstract][Full Text] [Related]
19. Glutamate receptor subunit 3 (GluR3) immunoreactivity delineates a subpopulation of parvalbumin-containing interneurons in the rat hippocampus.
Moga DE; Janssen WG; Vissavajjhala P; Czelusniak SM; Moran TM; Hof PR; Morrison JH
J Comp Neurol; 2003 Jul; 462(1):15-28. PubMed ID: 12761821
[TBL] [Abstract][Full Text] [Related]
20. Functional hemispherectomy: radical treatment for Rasmussen's encephalitis.
Lilly DJ
J Neurosci Nurs; 2000 Apr; 32(2):89-92. PubMed ID: 10826294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
